Premature Menopause vs Premature Ovarian Insufficiency: What the Two Terms Actually Mean

Premature menopause vs premature ovarian insufficiency is not a clean either-or. POI is the preferred term for loss of ovarian activity before 40 and may include intermittent periods, ovulation, or pregnancy. Some authorities reserve “premature menopause” for permanent cessation; others use it as an older or umbrella term. The label alone cannot tell you which applies.

What is the difference in 30 seconds?

POI allows for intermittent ovarian activity in some nonsurgical cases; “premature menopause,” used strictly, means ovarian function has ended permanently before 40. Because trusted authorities do not use the phrase consistently, the label alone cannot settle fertility, permanence, or diagnosis.

Your question right now	Premature ovarian insufficiency (POI)	“Premature menopause,” used strictly
Can ovarian activity still occur?	Yes, in some nonsurgical cases	No—the strict meaning is permanent cessation
Can periods or ovulation occur?	They may occur intermittently	No, under the strict definition
Can natural pregnancy occur?	Substantially less likely, but still possible in some nonsurgical cases	No, when ovarian function is permanently absent
Can the label alone tell me which situation I have?	No	No—because other authorities use the phrase as a name for POI
What settles it?	Age, cycle history, cause, clinical context, and current diagnostic criteria	The underlying facts—not the wording alone

Read that fourth row twice. It is the whole page.

That is the answer. Here is the part almost nobody tells you.

The medical world does not use these words consistently. The current international POI guideline prefers premature ovarian insufficiency. MedlinePlus says POI and premature menopause are different. The Menopause Society places POI under a broader “premature menopause” heading. NICE uses the terms as synonyms. The U.S. billing code still uses failure.

So if you have read two trustworthy pages and gotten two answers, you did not miss something. The sources really do disagree. Below, we show you exactly where, dated and side by side—then give you the rule that still works when the words do not.

This page is for you if

• You are under 40—or were when this started—and your periods became irregular or stopped.
• A clinician used “premature menopause,” “POI,” “primary ovarian insufficiency,” or “premature ovarian failure,” and you are not sure what was meant.
• You received an FSH or AMH result and are trying to understand what it can actually establish.
• You had ovarian surgery, both ovaries removed, chemotherapy, or pelvic radiation and need to understand how that history changes the answer.
• You are trying to separate the diagnosis question from the fertility, contraception, and hormone-replacement questions that come after it.

This page is not for you if

• You are over 45 and asking about ordinary menopause timing → read the average age of menopause and why sources disagree instead.
• You already had both ovaries removed and mainly need the after-surgery plan → read what changes after the ovaries are removed.
• You have heavy bleeding, severe pelvic pain, fainting, a possible pregnancy, or another urgent symptom. Contact a clinician or urgent-care service now.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What did The HRT Index actually verify for this page?

We checked the terminology against seven current medical and coding sources, then used the current international POI guideline for diagnosis and management. Provider prices, eligibility rules, insurance limits, program scope, and cancellation terms were checked against the providers’ own current pages and dated August 2026.

We do not want you taking our word for any of this, so here is exactly what we checked.

• We used the current ASRM/ESHRE evidence-based POI guideline for diagnosis, fertility, genetic and autoimmune evaluation, hormone therapy, bone monitoring, cardiovascular follow-up, and surgical POI.
• We compared the terminology used by MedlinePlus, The Menopause Society, NICE, Mayo Clinic, Cleveland Clinic, and the FY2026 U.S. ICD-10-CM classification.
• We checked the current evidence on AMH and natural conception against the ASRM ovarian-reserve committee opinion and the prospective Time to Conceive cohort.
• We checked current public pricing, age eligibility, insurance language, medication-category disclosures, lab inclusion, and cancellation terms for Sesame and Midi Health in August 2026.
• We kept FDA-approved and compounded medication in separate regulatory categories. The FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality in the same way as approved drugs.
• Where credible sources disagree, we show the disagreement. We do not pick one sentence, hide the others, and call that certainty.
• What we did not do: diagnose anyone, turn one laboratory number into a diagnosis, invent a clinical review, fabricate a testimonial, or create a provider score.

Find an error? Tell us at /corrections/.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Find My HRT Path is a routing tool, not a POI diagnosis or treatment recommendation. It takes about 90 seconds, requires no email to see the result, and its health answers are handled under our consumer health data privacy policy.

Premature menopause vs premature ovarian insufficiency: are they the same thing?

Sometimes the phrases point to the same clinical situation, and sometimes they do not. POI is the preferred specialist term for loss of ovarian activity before 40. Some sources reserve “premature menopause” for permanent menopause before 40; others use it as a synonym or umbrella term. The underlying facts must be clarified before the label means anything useful.

Seven differences that actually change the answer

Decision fact	Premature ovarian insufficiency	“Premature menopause,” used strictly
1. Preferred language	POI is the current specialist term	Common phrase, but medically ambiguous
2. Permanence	Ovarian activity may be intermittent in nonsurgical POI	Implies permanent cessation
3. Periods	May be absent, irregular, or occasionally return	Permanently stopped under the strict definition
4. Ovulation and natural pregnancy	Substantially less likely, but possible in some nonsurgical cases	Not possible when ovarian function is permanently absent
5. Diagnosis	Requires age, cycle history, and biochemical confirmation—or bilateral ovarian removal before 40	The phrase has no separate universal laboratory rule because sources use it differently
6. Cause	Can be spontaneous, genetic, autoimmune, treatment-caused, or surgical	May describe spontaneous permanent menopause or induced/surgical menopause, depending on the source
7. Care implications	Fertility and contraception can both matter; HT and long-term monitoring are usually discussed	Care still depends on the actual cause, age, uterus status, cancer history, and whether ovarian function is permanently absent

The seven-source definition ledger

Seven source systems. The same cluster of words. Several different structures. Every row checked in August 2026.

Source	Term it uses	How it treats the relationship	Practical meaning
ASRM/ESHRE international guideline	Premature ovarian insufficiency	Recommends POI for loss of ovarian activity before 40 and separates it from usual-age menopause	This is the current diagnostic and management framework used throughout this page
MedlinePlus / NIH	Primary ovarian insufficiency	Says POI is different from premature menopause: occasional periods and pregnancy may occur with POI, but not with premature menopause	A strict two-condition model
The Menopause Society topic page	Premature menopause as the heading	Places induced menopause and primary ovarian insufficiency beneath the broader heading	An umbrella-with-branches model
NICE	Premature ovarian insufficiency	Uses premature menopause and premature ovarian failure as alternate names for POI before 40	A synonym model
Mayo Clinic	Primary ovarian insufficiency / premature ovarian failure	Uses the same strict distinction as MedlinePlus	A strict two-condition model
Cleveland Clinic	Primary ovarian insufficiency	Distinguishes POI from premature menopause because ovarian activity may still occur with POI	Another strict two-condition model
FY2026 ICD-10-CM	Primary ovarian failure / premature menopause	Places premature-menopause codes inside the primary-ovarian-failure category	An administrative hierarchy, not a modern clinical definition

So what is actually true?

The sources overlap on the clinical territory: ovarian activity has been lost or impaired earlier than expected. They do not agree that every use of “premature menopause” describes the same biological state.

The word menopause tends to carry three assumptions:

1. It is permanent.
2. Fertility is finished.
3. This is the usual life transition, only earlier.

For many women with nonsurgical POI, the first two assumptions may be wrong. The third is wrong outright. POI is a medical condition with distinct fertility, bone, cardiovascular, psychological, and treatment implications. It is not simply ordinary menopause arriving ahead of schedule.

The rule that works no matter which framework your clinician uses

Do not read permanence, infertility, or diagnostic certainty into the label. Ask three questions instead: Is ovarian activity considered permanently absent or potentially intermittent? How was the diagnosis confirmed? Was it spontaneous, treatment-caused, or surgical?

Those answers matter. The word alone does not.

Not sure whether this is a diagnosis question, a fertility question, or an ongoing-care question? Find My HRT Path separates those routes and flags when online care is not the right starting point. → Find the right care path for my situation

What happened to “premature ovarian failure”?

“Premature ovarian failure” is older clinical language. It is no longer the preferred term because “failure” sounds total and permanent, while nonsurgical POI can include intermittent ovarian activity. The wording still appears in the U.S. code set, so it may show up on a chart or insurance claim even when the clinician says “insufficiency.”

If you were told “premature ovarian failure” and came here checking whether the newer term means something better—it does, a little. The biology did not change. The newer word is less likely to overstate what is known.

Why both primary and premature shorten to POI

Fuller Albright used primary ovarian insufficiency in a 1942 paper. The two P-words answer different questions:

• Primary points to the ovary as the site of the problem, rather than a failure of the brain or pituitary signal above it.
• Premature points to timing: before age 40.

“Primary” tells you where. “Premature” tells you when. They are not rival diagnoses.

U.S. patient resources still commonly use primary. The current international guideline recommends premature. Both are abbreviated POI.

Why your chart may still say “failure”

Because administrative language moves more slowly than clinical language.

Current FY2026 code	Wording in the code set	What it means administratively
E28.3	Primary ovarian failure	Parent category
E28.31	Premature menopause	Non-billable parent beneath E28.3
E28.310	Symptomatic premature menopause	Billable code with symptoms
E28.319	Asymptomatic premature menopause	Billable code without symptoms
E28.39	Other primary ovarian failure	Other conditions in the category
E89.40 / E89.41	Postprocedural ovarian failure, asymptomatic / symptomatic	Separate category for postprocedural loss of ovarian function
N95.1	Menopausal and female climacteric states	Usual menopausal and climacteric states—not the POI category

Three things this tells you:

1. Your paperwork may say “failure” even when your clinician says “insufficiency.” The codebook is not secretly telling you something worse.

2. The code hierarchy is not a clean clinical definition. It puts “premature menopause” beneath “primary ovarian failure,” while MedlinePlus separates the two.

3. Symptoms are not required for a code. E28.319 exists for asymptomatic premature menopause. Feeling fine does not make a confirmed diagnosis impossible.

There is movement, just not yet. In March 2026, the CDC approved adding primary ovarian insufficiency as an inclusion term beneath E28.3, effective October 1, 2027. Until then, older wording remains in the active classification.

Where does early menopause fit?

*POI describes loss of ovarian activity before age 40. Current international guidance uses early menopause for ages 40 through 44. The age boundary is a convention, not a biological force field: reaching 40 changes the category name, not the need to address symptoms, bone health, cardiovascular risk, fertility, or treatment.*

Age or situation	Current practical term
Under 40 with disordered cycles and biochemical ovarian insufficiency	Premature ovarian insufficiency
Ages 40–44 with menopause	Early menopause
Menopause outside the premature or early categories	Usual-age menopause; timing varies by population
Both ovaries removed before 40	Surgical menopause and POI under the international guideline
Ovarian damage after chemotherapy or radiation before 40	Treatment-caused or iatrogenic POI; ovarian activity may or may not recover depending on the treatment and individual

The 12-month rule does not apply here

This one traps a lot of women, so let us kill it now.

You have read that menopause is confirmed after 12 months without a period. That is the retrospective rule for ordinary spontaneous menopause.

The current POI criteria begin after at least four months of absent or irregular cycles, not twelve. The Menopause Society advises women under 40 who have missed three or more periods to seek evaluation for POI or another cause.

If you are under 40 and your periods have stopped or become persistently irregular, you are not supposed to sit at home and wait out a year.

How is premature ovarian insufficiency actually diagnosed?

Current international guidance uses two required pieces: spontaneous absent or irregular cycles for at least four months, plus FSH above 25 IU/L. One elevated result can satisfy the biochemical part when the clinical picture fits; FSH is repeated after four to six weeks if uncertainty remains. A laboratory number without the cycle history is not the diagnosis.

The current criteria

POI diagnostic criteria - Loss of ovarian activity before age 40 - Spontaneous amenorrhea or irregular menstrual cycles for at least four months - FSH above 25 IU/L - Repeat FSH after four to six weeks when the diagnosis remains uncertain - No requirement to test on a specific cycle day

Why older records and clinicians may use different thresholds

Framework	Laboratory approach	What to know in 2026
Current ASRM/ESHRE guideline	FSH above 25 IU/L with at least four months of disordered cycles; repeat only if uncertainty remains	Current international standard used on this page
NICE	Two elevated FSH measurements four to six weeks apart; its guidance has used a higher threshold than the current international guideline	Still encountered in UK practice and older summaries
Previous ESHRE guidance and older references	Often required two elevated results, commonly using thresholds from 25 to 40 IU/L	Explains why old charts and older web pages may demand a second draw or a higher number

Now look at a real number.

An FSH of 28 IU/L crosses the current guideline’s biochemical threshold. It does not diagnose POI by itself. The woman must also be under 40, have at least four months of spontaneous absent or irregular cycles, and have the result interpreted in context.

That distinction is not nitpicking. It is the difference between a laboratory cutoff and a diagnosis.

Five practical things about testing

Pregnancy is excluded first. A missed period under 40 is not automatically POI.

Hormonal medication can hide the picture. Oral, injectable, and long-acting contraception—and hormone therapy—can alter bleeding patterns and lower FSH. Some medication may need to be paused before confirmation, but only under the direction of the clinician ordering the evaluation.

Estradiol supports the picture but cannot establish POI alone. A low estradiol level can support evidence of low-estrogen status. It is not the sole diagnostic test.

AMH is not the primary diagnostic test. The guideline says AMH may help when FSH is inconclusive, but it must be interpreted in clinical context and should not be used routinely to predict POI.

One normal period does not erase POI. Intermittent ovarian activity can occur in nonsurgical cases.

If both ovaries were removed before 40

You are not in a grey area. The current guideline states that bilateral salpingo-oophorectomy before 40 establishes POI. No FSH test or four-month wait is required to prove the loss of ovarian function. The next conversation is treatment suitability, fertility implications, symptom control, and long-term monitoring.

Does your situation need diagnosis, fertility care, or ongoing HRT management? Find My HRT Path will route you toward the right kind of next step and tell you when online care should not come first. → See which care path fits

My AMH came back low. Does that mean I have POI?

No. Low AMH on its own is not POI. AMH is an ovarian-reserve marker; POI requires the compatible cycle pattern plus biochemical confirmation. Ovarian-reserve tests are useful for estimating likely response to ovarian stimulation, but they are poor independent predictors of whether a woman without diagnosed infertility will conceive naturally.

This section exists because low-AMH panic sends women down the wrong road—and sometimes toward expensive products that cannot deliver what the marketing implies.

POI vs diminished ovarian reserve

	POI	Diminished ovarian reserve (DOR)
Period pattern	Often absent or irregular for at least four months; ovarian activity may still fluctuate	May remain regular
Main question	Is ovarian activity impaired before 40?	Is the estimated remaining follicular pool lower than expected?
Core diagnostic evidence	Cycle history plus FSH under current criteria	AMH, antral follicle count, and other reserve measures interpreted in context
Does it equal infertility?	Natural conception is substantially less likely, but nonsurgical conception can occur	No; the finding does not independently establish inability to conceive
Can AMH alone settle it?	No	AMH supplies reserve information, not a complete natural-fertility forecast

AMH is often described as measuring “how many eggs are left.” That is too literal. It is a biomarker related to the pool of small growing follicles. It does not count every remaining egg, tell you egg quality, or produce a personal monthly pregnancy probability.

The study worth knowing before you panic

The prospective Time to Conceive study followed 750 women ages 30 to 44 who had been trying to conceive for three months or less and had no known history of infertility. Women with low AMH—below 0.7 ng/mL—or FSH above 10 mIU/mL did not have significantly lower predicted cumulative conception probabilities after six or twelve cycles than women with normal results.

That study does not mean AMH never matters. It means this:

A low ovarian-reserve marker is not a verdict that natural pregnancy is impossible.

ASRM’s practical conclusion is that ovarian-reserve tests predict the number of oocytes likely to be retrieved during stimulation much better than they predict natural conception in women who have not been diagnosed with infertility.

Things you may have read that are wrong

• ❌ “Low AMH means you have POI.” — No. They are different findings.
• ❌ “Normal AMH rules out POI.” — No.
• ❌ “One period means my ovaries recovered.” — No. Intermittent activity can be part of POI.
• ❌ “POI means I have no eggs.” — No. It means ovarian activity is impaired.
• ❌ “AMH tells me my personal chance of pregnancy this month.” — No.

Can you still get pregnant with premature ovarian insufficiency?

Yes, natural pregnancy can occur in some women with nonsurgical POI, but the chance is low and cannot be predicted reliably for an individual. The Menopause Society describes natural pregnancy as occurring in fewer than 10% of women with POI. After both ovaries are removed, natural conception is no longer possible.

This is the clearest reason insufficiency is often more accurate than menopause. It leaves room for ovarian activity that can appear and disappear without becoming predictable.

What “less than 10%” means—and what it does not

The Menopause Society gives a population estimate of less than 10%. Older professional guidance and reviews often report 5% to 10%. The current international guideline does not endorse one universal percentage; it states that ovarian activity may occur in nonsurgical POI and that natural conception remains possible.

That number is:

• A population estimate across time
• Not your monthly odds
• Not a promise that ovarian activity will return
• Not a reason to delay fertility care when pregnancy matters to you
• Not proof that one treatment can trigger the return

Hormone therapy is not birth control

HRT does not prevent natural conception in POI. The current guideline says this directly.

Read that again if you are using HRT and do not want a pregnancy.

Absent periods are not contraception. Irregular periods are not contraception. HRT is not contraception. A clinician can help choose a contraceptive plan that also accounts for the need for adequate estrogen replacement.

If a combined oral contraceptive is used in POI, the guideline recommends a continuous or extended regimen to avoid hormone-free gaps that could work against bone protection. That is a prescribing decision, not a reason to change your regimen on your own.

If both ovaries were removed

Natural conception is no longer possible. We are not going to soften that.

Pregnancy may still be possible, when medically appropriate, through donated oocytes or embryos, or through eggs or embryos preserved before surgery or treatment. Some women also need pre-pregnancy assessment because Turner syndrome, previous cancer treatment, or radiation involving the uterus can change cardiovascular or obstetric risk.

If pregnancy is what you actually came here for

Then the clinician you need is usually a reproductive endocrinologist, and sooner is better than later. A general menopause subscription is not built to answer the complete fertility question.

The current guideline recognizes oocyte donation as an established pregnancy option after POI. It also says no intervention has been reliably shown to increase ovarian activity or natural-conception rates after the diagnosis.

If fertility is your first question, that changes which door you should knock on. Find My HRT Path will flag the specialist-first route rather than pushing you toward an ordinary online HRT intake. → Find the right specialist path

How common is POI, really?

The old “1 in 100” estimate is not the only current figure. The international guideline says older studies reported about 1%, while recent publications put non-iatrogenic POI around 3.5%. Other recent meta-analyses and The Menopause Society place the estimate roughly between 3% and 4%, depending on definitions and populations.

Estimate	Source	What the figure describes
About 1%	Older studies	The legacy estimate still repeated on many pages
3.7%	2019 meta-analysis of 31 studies	Pooled primary ovarian insufficiency prevalence; methods and populations varied
About 3.5%	2023 meta-analysis and current international guideline	Recent global estimate for POI / non-iatrogenic POI
About 3 in 100	The Menopause Society	Patient-facing estimate for menopause before 40
About 4 in 100	ESHRE patient guidance	Rounded patient-facing estimate

The estimate did not change because women suddenly became four times more likely to develop POI. It changed because definitions, case-finding, populations, and study methods changed.

Practical translation: the “one in a hundred” line may understate how many women share this experience. You are not as alone as the oldest number makes you feel.

Why can POI take so long to diagnose?

POI is often delayed because irregular periods in a young woman are attributed to stress, contraception, weight change, polycystic ovary syndrome, or “being too young” before ovarian insufficiency is considered. A small but influential survey found repeated visits and multi-year delays; newer bone data show why delay matters even when symptoms are mild.

We include this section for one reason: you may think you should have caught it sooner, or that you are being dramatic. Neither conclusion follows from the evidence.

The delay survey—and its limits

A 2002 survey included 48 women with spontaneous POI. It was small, old, and recruited a highly educated sample, so it should not be treated as a modern national prevalence survey. It remains useful because it documented a pattern that current reviews still recognize:

• 92% said menstrual disturbance was the first symptom they noticed.
• More than half reported at least three clinical visits before laboratory testing was ordered.
• More than half had seen at least three clinicians before diagnosis.
• One quarter reported that more than five years passed before confirmation.

That does not prove every woman faces the same delay. It proves the delay is not an invention of women who felt dismissed.

What delay can cost

A 2025 retrospective single-center study reviewed 168 women with POI or early menopause; 125 had bone-density testing. At diagnosis, 43.1% had osteopenia and 10.3% had osteoporosis. A longer interval to diagnosis was associated with lower bone mineral density.

The study cannot prove that every month of delay directly caused bone loss, and it came from one center. It still supports the practical point: a young woman with persistent cycle disruption should not be told to wait indefinitely because she “looks too young” for ovarian insufficiency.

“You are too young for that”

If you have heard this, here is a sentence that reopens the conversation without turning it into a fight:

“I understand POI is uncommon at my age. Can we review whether I meet the current four-month cycle criterion, order or interpret FSH in that context, and tell me what other causes you are considering?”

Specific questions are harder to wave away.

What causes premature ovarian insufficiency?

POI may be spontaneous and unexplained, genetic or chromosomal, autoimmune, surgical, or caused by chemotherapy or radiation. MedlinePlus estimates that the exact cause is unknown in about 90% of cases; the current international guideline uses the more cautious wording that an exact cause may not be identified.

“We do not know” is a real answer

An unexplained diagnosis does not mean nothing happened. It means the tests available today did not identify the cause.

It also does not mean you caused this by being stressed, using an IUD, taking birth-control pills, exercising, changing your diet, or waiting to have children. Those are not established POI causes in the current guideline. Hormonal contraception can mask cycle changes and complicate testing; that is different from causing the ovarian insufficiency.

Smoking is a recognized modifiable risk factor for earlier ovarian aging. That does not make every case in a smoker self-inflicted, and stopping cannot reverse follicle loss that has already occurred. It changes the risk going forward.

Known cause groups

Medical treatment or surgery. Removal of both ovaries causes immediate, permanent loss of ovarian activity. Other ovarian surgery, chemotherapy, and pelvic radiation can damage ovarian follicles. The effect depends on the treatment, dose, field, age, and baseline ovarian reserve. Ovarian activity may recover after some treatments and not others.

Genetic or chromosomal causes. These include Turner syndrome, chromosomal variation, and the FMR1 premutation associated with fragile X–related disorders. A finding can matter to relatives, which is why counseling belongs before or alongside genetic testing.

Autoimmune causes. Autoimmune adrenal disease and thyroid disorders can occur with POI. Current guidance recommends targeted testing rather than a vague “autoimmune panel.”

Unexplained spontaneous POI. This remains the most common category in many patient-facing sources.

Family history matters—but it is not destiny

The current guideline advises that sisters and daughters of women with non-iatrogenic POI be told that their risk is increased. If a specific genetic cause is identified, relatives should be offered genetic counseling and testing. An increased risk is not a prediction that the same thing will happen to every relative.

What tests should come after the diagnosis—and what often gets missed?

Confirming POI is the start of the workup, not the end. For non-iatrogenic POI, the international guideline recommends chromosomal analysis and FMR1 premutation testing. When the cause is unknown, it recommends 21-hydroxylase antibodies, along with thyroid assessment and baseline bone-density testing.

This is the most actionable table on the page. Bring it to the appointment.

Evaluation	What the current guideline says	What the result changes
Chromosomal analysis	Recommended for all women with non-iatrogenic POI	May identify a chromosomal cause and change counseling or monitoring
FMR1 premutation testing	Recommended for all women with non-iatrogenic POI	May affect the woman and biological relatives; counseling matters
Additional genetic testing	May be offered where available after comprehensive counseling	May identify less common genetic causes
21-hydroxylase antibodies	Recommended when the cause is unknown	A positive result should lead to endocrinology assessment of adrenal function
Repeat 21-hydroxylase antibodies after a negative test	Not recommended unless symptoms of adrenal insufficiency later appear	Avoids repeated testing without a clinical reason
TSH	Check at diagnosis; repeat every five years or sooner if symptoms arise	Detects thyroid dysfunction that may need treatment
Routine thyroid-peroxidase antibodies	Not routinely recommended solely as part of the POI autoimmune workup	Positive tests are common in the general population and may not clarify the cause
Anti-ovarian antibodies	Not recommended for diagnosing autoimmune POI	The test does not reliably establish autoimmune POI
DXA bone-density scan	Recommended at diagnosis where available	Establishes whether bone follow-up or specialist care is needed

Two notes matter.

Counseling belongs before genetic testing, not as damage control after the result. A result may carry information about sisters, daughters, brothers, pregnancy planning, and fragile X–related conditions.

This is a list to ask about, not a direct-to-consumer shopping list. A panel without the right interpretation and follow-up can create more fear without creating a plan.

Is hormone therapy different when it is POI?

Yes. In POI, hormone therapy is usually replacing hormones lost decades earlier than expected—not simply treating hot flashes during the usual menopause transition. The current guideline recommends HT until the usual age of menopause for most women with POI, including women without obvious symptoms, unless an individual contraindication changes the plan.

Most women arrive here carrying twenty years of frightening hormone headlines. Those headlines were largely built from a different population. We will get to that. First, the practical difference.

Replacement, not just symptom treatment

A woman who reaches menopause around the usual age may use HT primarily for symptoms and quality of life.

A woman who loses ovarian activity at 28 or 35 is facing years in which her ovaries would ordinarily still be producing sex hormones. In that setting, the treatment discussion includes bone, cardiovascular, neurological, sexual, and overall health—not only whether she has hot flashes.

Those are different clinical situations. The guideline treats them differently.

The dose difference worth asking about

For bone protection in POI, the current guideline conditionally suggests a daily HRT dose containing no less than 2 mg oral estradiol or 100 micrograms of transdermal estradiol, or an equivalent regimen.

That is not a universal prescription. It is a guideline-level reference range for optimizing bone mineral density, and individual factors can change route and dose.

We are not telling you what to take. We are giving you the question that belongs in the room:

“Because this is POI rather than usual-age menopause, is my regimen providing the replacement level the current guideline describes for bone health?”

Your prescriber makes the call.

The other things worth knowing

• If you have a uterus, systemic estrogen is generally paired with a progestogen to protect the endometrium.
• HRT is not contraception. If pregnancy is not desired, contraception needs its own plan.
• Migraine is not automatically a reason to withhold HT. For migraine with aura, the guideline suggests transdermal estrogen as the lowest-risk route.
• Breast-cancer risk is not framed the same way as it is for older postmenopausal populations. The guideline states that there is no evidence HT increases breast-cancer risk in women with POI compared with same-age women without POI. A personal history of breast cancer or another hormone-dependent tumor changes the conversation and generally requires specialist input.
• If a combined oral contraceptive is used, the guideline recommends a continuous or extended regimen for continuous estrogen exposure and bone protection.
• If you had cancer treatment, HT suitability depends on the cancer type, hormone-receptor status, treatment history, and oncology plan.

FDA-approved and compounded hormones are not the same regulatory category

The POI guideline does not recommend compounded estrogen or progesterone because efficacy and safety information is insufficient.

The FDA’s position is separate and equally clear: compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness, or quality before marketing in the way it does for approved drugs. Compounded medication can meet a legitimate patient need when an FDA-approved product is not medically appropriate, but it should never be presented as automatically safer, more natural, or equivalent.

A telehealth company may offer FDA-approved prescriptions, compounded prescriptions, or both. The category applies to the specific medication, not to the company as a whole. Ask which one is being proposed before you pay.

For the broader treatment tradeoffs, read how HRT benefits and risks are evaluated.

Until what age should hormone therapy continue?

Current guidance recommends HT until the usual age of menopause, then a fresh individualized decision about whether to continue. For many women in the United States, that reassessment happens around age 50 or 51. Reaching that age does not create an automatic stop date; it changes the reason for the decision.

Before the usual age of menopause, the goal is to replace hormones lost earlier than expected and reduce the health consequences of untreated POI.

Around the usual menopause age, the question becomes the same individualized risk-benefit question faced by other women: current symptoms, bone health, cardiovascular history, bleeding, cancer history, medication route, dose, and personal preference.

At 51, the decision restarts. It does not automatically end.

The current guideline also says delayed initiation and non-adherence should be avoided. That does not mean every missed dose causes permanent harm. It means long gaps and quiet treatment drift deserve a deliberate review rather than becoming the plan by accident.

If you stopped months or years ago because a prescription expired, a clinician moved, or a frightening headline got into your head, that is worth reopening. Not with guilt. Just reopening.

Does the Women’s Health Initiative apply to POI?

The Women’s Health Initiative does not answer the POI hormone-replacement question. Its hormone trials enrolled women ages 50 to 79, with an average age around 63—not women replacing ovarian hormones in their 20s or 30s. A 2024 review by original WHI investigators says those results should not be extrapolated to premature or early menopause because that population was not studied.

This is worth being precise about because it is the fear that stops some women from taking treatment their clinician recommends.

The WHI changed medicine. It also became a cultural shorthand for “hormones are dangerous,” stripped of age, formulation, timing, route, and clinical purpose.

The trial that frightened you was not a trial of women with POI.

That does not make HT risk-free. It means the risk-benefit question for a 31-year-old replacing hormones after ovarian insufficiency cannot be answered by treating her as a 63-year-old starting a specific WHI regimen years after menopause.

If a clinician cites “the WHI” as the entire reason to withhold HT from a young woman with POI, ask how the evidence is being applied to a population the trial did not study.

Does that sound like the wall you have hit? Find My HRT Path can separate specialist-first care from ongoing online management and will say plainly when a subscription clinic is not the right place to start. → See which care route fits

What are the long-term health risks, honestly?

POI is associated with higher risks involving bone, cardiovascular, neurological, sexual, and psychological health. Those are group-level associations, not a forecast of one woman’s future. The point of naming them is not to frighten you—it is to explain why diagnosis, adequate hormone replacement when appropriate, and follow-up matter even when symptoms are mild.

Bone

A 23-year Australian cohort included 8,603 women, including 610 with POI or early menopause. By follow-up, 49.7% of the POI/early-menopause group had osteoporosis or a fracture, compared with 36.6% of women with usual-age menopause. Adjusted analyses found higher odds of osteoporosis and fracture.

Separately, the 2025 diagnosis-cohort study found osteopenia in 43.1% and osteoporosis in 10.3% of those who received DXA testing around diagnosis.

These findings support the guideline’s recommendation for baseline DXA and adequate systemic HT when appropriate. They do not mean half of every treated woman with POI will suffer a fracture.

Cardiovascular health

A UK Biobank analysis included 144,260 postmenopausal women. Cardiovascular disease occurred in 6.0% of women with natural menopause before 40, compared with 3.9% of women without premature menopause. After adjustment, natural premature menopause was associated with a higher cardiovascular risk; surgical premature menopause carried a larger association.

This was observational research. It cannot assign one woman a personal fate or prove that age at menopause caused every event. It supports taking blood pressure, smoking, weight, lipids, diabetes risk, and hormone-replacement decisions seriously.

Brain, mood, sexuality, and quality of life

The guideline recognizes associations with cognitive and neurological outcomes and recommends attention to psychological, sexual, and genitourinary health. The diagnosis itself can also hit identity, relationships, fertility plans, body image, and a woman’s sense of time.

That impact is not a side note. The guideline specifically calls for compassionate delivery of the diagnosis, time for questions, shared decision-making, support groups, and mental-health care when needed.

How to read every risk number on this page

• These are population findings.
• Observational studies can carry residual confounding.
• Treatment exposure, timing, adherence, and cause of POI differ across cohorts.
• The numbers do not predict an individual outcome.
• They explain why doing nothing by drift is not the same as making an informed choice.

These figures are the argument for completing the workup and protecting your future health. They are not a prophecy about your life.

Does surgical menopause count as POI?

Yes, when both ovaries are removed before age 40. The current international guideline says bilateral salpingo-oophorectomy before 40 establishes POI and no additional diagnostic testing is needed. The same event is also accurately described as surgical or induced menopause.

Two practical consequences follow.

You skip the diagnostic maze. There is no FSH-threshold argument and no four-month wait. The fact of bilateral ovarian removal answers whether ovarian activity is permanently absent.

The hormone change is abrupt. Spontaneous POI can fluctuate. Bilateral removal ends ovarian hormone production immediately, so symptoms can arrive suddenly and the treatment conversation often begins before or immediately after surgery.

What does not become simple is everything around the diagnosis: cancer history, inherited cancer risk, endometriosis, uterus status, fertility preservation completed before surgery, contraindications, dose, route, and monitoring.

For the full after-surgery guide, read what changes after the ovaries are removed.

Can premature ovarian insufficiency be reversed?

No treatment has been reliably shown to restore ovarian activity or increase natural-conception rates after POI. Ovarian activity can recur spontaneously in some nonsurgical cases, but that is unpredictable fluctuation—not proof that a supplement, injection, diet, or clinic protocol reversed the condition.

A returning period is not the same thing as remission. It does not prove the condition is gone and does not predict what will happen next month.

Be careful here

This is exactly where frightened people get sold things.

Legitimate clinical trials exist. They use protocols, informed consent, eligibility criteria, oversight, and transparent uncertainty. A consumer clinic selling “ovarian rejuvenation,” a supplement stack promising to wake dormant ovaries, or a before-and-after fertility story is not the same thing.

The current guideline says no intervention has been reliably shown to increase ovarian activity and natural conception. Until high-quality evidence changes that conclusion:

Nobody can sell you your ovarian function back. If someone promises they can, the promise is the evidence problem.

What can this page—and online care—not do for you?

Time for the honest part.

This page cannot tell you whether you have POI, and no article can. We can show you the competing definitions, the current criteria, the code language, and the workup. We cannot establish whether your four-month cycle criterion is met, whether pregnancy and medication effects were handled correctly, or what caused the result in your body.

There is a harder version too.

If you came here because a clinician brushed you off, we cannot tell you from a paragraph that the clinician was wrong. Repeating FSH in four to six weeks can be the careful answer when the picture is uncertain. What we can give you is enough specificity to tell the difference between a reasoned plan and an endless stall.

Where online care falls short

Many online menopause services are built for symptom assessment and ongoing treatment, not for the complete initial POI evaluation. A full workup may involve chromosome analysis, FMR1 testing, adrenal antibodies, genetic counseling, DXA interpretation, reproductive planning, and coordination with oncology or endocrinology.

Capabilities vary. Do not turn that into the false claim that telehealth can never diagnose POI. A licensed clinician can evaluate and diagnose through telehealth when the service has the right scope, testing pathways, and escalation options. The problem is the model, not the camera.

One concrete age gate matters here: Midi Health states that it provides specialty care for women 35 and older. It is not an option for a 29-year-old, regardless of how appropriate its ongoing-care model might look later.

Diagnosis and cause evaluation first. Ongoing management second. Two jobs. Often two doors.

If the diagnosis is settled but the problem is a clinician who will not discuss appropriate treatment, read what to do when a doctor will not prescribe HRT.

What should you do next based on where you are?

The right next step depends on whether the diagnosis is confirmed, whether the cause-and-monitoring workup is complete, whether fertility or contraception is the immediate priority, and whether you need specialist evaluation or ongoing treatment management. The label on the chart is not enough to choose the door.

Your situation	Best next step	Do not assume
Under 40 with new absent or irregular periods and no diagnosis	Arrange an evaluation with an OB-GYN, reproductive endocrinologist, or clinician experienced in POI	That this is ordinary perimenopause or that you must wait 12 months
FSH above 25 but less than four months of cycle disruption	Ask how the result is being interpreted and what follow-up is planned	That the laboratory threshold alone completes the diagnosis
Four months of disrupted cycles plus FSH above 25	Ask whether the clinician considers the current criteria met and whether uncertainty requires repeat testing	That the cause-and-health workup ended with FSH
Low AMH with regular periods	Discuss ovarian reserve and reproductive goals	That low AMH equals POI or predicts natural conception by itself
Confirmed nonsurgical POI and trying to conceive	See a reproductive endocrinologist promptly	That HRT prevents pregnancy or a commercial protocol can reverse POI
Confirmed nonsurgical POI and avoiding pregnancy	Discuss contraception separately from HRT	That absent periods or HRT provide contraception
Both ovaries removed before 40	Move to treatment suitability, fertility implications, and long-term monitoring	That another FSH or AMH test is needed to prove ovarian loss
POI after chemotherapy or radiation	Coordinate with oncology or survivorship care plus reproductive or menopause specialists	That every treatment-caused case has the same fertility or HT implications
Possible genetic or autoimmune cause	Ask about counseling, chromosomal analysis, FMR1, 21-hydroxylase antibodies, and thyroid testing	That an unsupervised consumer panel is a substitute for interpretation
Under 35 and considering Midi	Use another diagnostic or specialist route	Midi’s published care model is for women 35+
Confirmed diagnosis, age 35+, workup complete, seeking ongoing HRT management	Telehealth may be reasonable if the provider’s scope, medication category, insurance, and follow-up fit	That every telehealth service manages complex POI or offers the same medications
Personal history of breast cancer or another hormone-dependent tumor	Start with oncology and the relevant specialist	That general POI hormone guidance applies unchanged
Medicare, Medicaid, or Medi-Cal coverage	Start with an in-network specialist or covered health system when available	That a cash-pay affiliate route will be cheaper or accepted by every provider

Who should leave this page without clicking a provider

We would rather lose the commission than waste your time.

If you are under 40, do not have a confirmed diagnosis, and need the full cause-and-fertility workup, do not choose an ordinary menopause subscription because the landing page feels easy. Choose the clinician and care setting that can answer the unfinished medical questions.

If fertility is the first question, do not let a hormone-management offer distract you from a reproductive endocrinologist.

If you already have a clinician, coverage, and a complete plan, do not pay a new platform merely because it is linked here.

The right reader for online ongoing management is the woman whose diagnostic questions have been answered and whose next problem is access, continuity, monitoring, or prescription management.

Where can you get care—and where would we start?

For most women with suspected POI, the strongest first route is a reproductive endocrinologist, an OB-GYN, or another clinician who can complete the diagnostic and cause evaluation. Telehealth becomes more useful when it either provides that scope explicitly or takes over ongoing management after the diagnosis and specialist plan are established.

We may earn a commission if you use a labeled provider link below. That does not change the facts we verified or the order of the recommendation. Read our affiliate disclosure.

Provider-stated vs verified: the two online routes that fit a narrow part of this page

Provider	What the provider currently states	What we verified in August 2026	Material limitation	Best fit here
Sesame fertility program	Virtual fertility care with an initial visit, unlimited messaging, fertility planning, lab ordering, medication management, and IVI RMA referral coordination	$119/month, or $99/month for Costco members; virtual program available in all 50 states; common orders may include AMH, FSH, TSH, estradiol, and prolactin; subscription is cash-pay	Laboratory charges, medications, HSG, IUI/IVF, egg retrieval, genetic testing, and cryopreservation/storage are not included. Provider credentials and specialist scope vary. It is not a promise that chromosome, FMR1, adrenal, DXA, or advanced fertility evaluation will all be completed inside the subscription	A virtual first fertility-oriented evaluation or bridge to specialist care when local access is slow—not a replacement for an REI when advanced evaluation is needed
Midi Health	Virtual specialty care for women 35+, with menopause-trained clinicians, lab or imaging orders when indicated, and referrals for in-person care	Self-pay is $250 for the initial visit and $150 for continued-care visits; in-network with most PPO plans, subject to plan cost-sharing; available in all 50 states	Cannot treat Medicaid or Medi-Cal patients, even self-pay. Medicare beneficiaries may self-pay but cannot submit related claims. Midi offers FDA-approved HRT prescriptions and, separately, compounded estrogen/progesterone options; ask which category is proposed. Medication and laboratory costs are separate unless covered.	A woman 35+ with a confirmed diagnosis and completed workup who wants ongoing video-based HRT management and plan-specific insurance billing

Sesame: for a fertility-oriented virtual starting point

Sesame’s current fertility subscription is not the same as booking a guaranteed reproductive endocrinologist. It can be useful when the first need is a virtual evaluation, common fertility labs, medication management, or a coordinated referral—but read the exclusion line before the price seduces you.

The $119 or $99 subscription price does not include the laboratory bill, medications, genetic testing, imaging or fertility procedures. POI can require tests outside the standard fertility-lab list. Ask the named clinician before booking whether they can coordinate the specific workup you need and whether they are a board-certified reproductive endocrinologist or another type of fertility clinician.

Sesame’s published refund rule says a cancellation made at least three hours before the initial visit receives a full refund. After the initial visit, the first month is not refundable. Future billing stops when the subscription is cancelled before the next billing cycle.

Need a virtual fertility-oriented appointment while you work toward specialist care? Check the clinician, credentials, price, and availability before paying. → Check Sesame fertility-care availability

Midi Health: for ongoing management after the diagnosis is settled

Read the age line first: Midi is for women 35 and older. If you are 34 or younger, it is not your route today.

For an eligible woman with confirmed POI and a completed workup, Midi may fit ongoing care: scheduled video visits, clinically indicated testing, between-visit coordination, prescription management, and PPO billing in many plans.

The self-pay prices are visit prices, not an all-inclusive POI package: $250 initially and $150 for continued care. Your exact insurance responsibility depends on the plan, deductible, copay, and coinsurance. Prescription and lab costs depend on the medication, pharmacy, order, and coverage.

Medication category requires a direct question. Midi publicly describes FDA-approved HRT routes and separately offers compounded estrogen and progesterone options. Do not ask whether “Midi is FDA-approved.” Ask whether the specific prescription proposed for you is an FDA-approved drug or a compounded preparation.

Midi asks patients to change or cancel a visit at least 24 hours in advance to avoid a cancellation fee.

If you are 35+, already diagnosed, and looking for ongoing management, verify your exact PPO network status and the medication category before booking. → Check Midi coverage and current visit cost

Free routes we make nothing from

• The Menopause Society practitioner directory — searchable directory of clinicians, including those with the MSCP credential.
• The Daisy Network — UK-based POI charity and support community with international reach.
• Ask Early Menopause — patient information and support developed with early-menopause and POI expertise.
• RESOLVE: The National Infertility Association — U.S. fertility information and support groups.

No commission on those. They are here because they may be the right answer.

What questions should you bring to your appointment?

The best appointment questions clarify what diagnosis your clinician means, what evidence supports it, whether ovarian activity may still occur, what caused it, and how fertility, contraception, hormone replacement, and long-term monitoring fit together. Bring your period timeline, medication list, laboratory reports, treatment history, and current pregnancy goals.

Copy the questions that apply.

About the words

• When you say “premature menopause,” do you mean POI with potentially intermittent ovarian activity or permanent menopause?
• Are you using primary and premature ovarian insufficiency to mean the same condition?
• Is “premature ovarian failure” simply the older chart or billing language in my case?

About the diagnosis

• Do I meet the current criteria: at least four months of absent or irregular cycles plus FSH above 25 IU/L?
• Is my FSH being treated as a biochemical threshold or as a complete diagnosis?
• Does FSH need repeating after four to six weeks because the picture is uncertain?
• Was pregnancy excluded?
• Could contraception or HRT have altered my bleeding pattern or FSH?
• What does estradiol add to the interpretation?
• Is AMH being used as ovarian-reserve information or as evidence of POI?
• What other causes of absent or irregular periods were considered?

About the cause

• Is this spontaneous, genetic, autoimmune, treatment-caused, or surgical?
• Should I have chromosomal analysis and FMR1 premutation testing?
• Can I have genetic counseling before or alongside testing?
• Do I need 21-hydroxylase antibodies and TSH?
• Does any result change what my relatives should be told?

About fertility and contraception

• Could ovarian activity still occur in my case?
• Should I see a reproductive endocrinologist now?
• Which established fertility options apply to me?
• Do I need contraception?
• Does my current HRT provide contraception? The expected answer is no.

About hormone therapy and monitoring

• Is HT recommended in my situation even if I feel well?
• Is my regimen providing the replacement level the POI guideline describes for bone health?
• If I have a uterus, what progestogen protection do I need?
• Is the proposed medication FDA-approved or compounded?
• Do I need a baseline DXA?
• When should DXA be repeated based on my result?
• Which blood-pressure, lipid, diabetes, and thyroid checks belong in my plan?
• What bleeding or symptom changes should trigger reassessment?
• What is the plan when I reach the usual age of menopause?

What else do women ask about premature menopause and POI?

The remaining questions usually concern permanence, pregnancy, FSH, AMH, hormone therapy, contraception, and whether telehealth can handle the next step. These answers keep the terminology conflict intact while giving a direct practical answer.

Is premature ovarian insufficiency the same as premature menopause?

Sometimes the phrases are used for the same condition, but not universally. The current international guideline prefers POI; MedlinePlus distinguishes POI from permanent premature menopause; The Menopause Society uses premature menopause as a broader heading; NICE uses the terms as alternatives. Ask what the label means in your case.

What is the difference between primary and premature ovarian insufficiency?

They generally describe the same condition and share the abbreviation POI. Primary emphasizes that the problem is at the ovary. Premature emphasizes that it occurred before 40. The current international guideline prefers premature ovarian insufficiency.

Is premature ovarian failure outdated?

It is older and no longer preferred clinical language because failure can imply a complete, permanent shutdown. It remains in the current U.S. ICD-10-CM parent-category wording, so it may still appear on charts and claims.

Why does my chart say “failure” when my clinician said “insufficiency”?

The active FY2026 code family still uses primary ovarian failure. A CDC-approved addition of primary ovarian insufficiency beneath that category is scheduled to take effect October 1, 2027. The older wording is an administrative artifact, not a hidden second diagnosis.

At what age is menopause considered premature?

Before age 40. Current international guidance calls menopause from ages 40 through 44 early menopause.

Do I have to wait 12 months without a period?

No. The 12-month rule is used retrospectively for usual-age spontaneous menopause. Current POI criteria use at least four months of absent or irregular cycles plus biochemical confirmation.

What FSH level indicates POI?

The current international guideline uses FSH above 25 IU/L together with at least four months of disordered cycles in a woman under 40. Repeat FSH after four to six weeks if uncertainty remains. The number alone is not the complete diagnosis.

Does an FSH of 28 mean I have POI?

It crosses the current biochemical threshold, but it does not establish POI by itself. Age, at least four months of spontaneous cycle disruption, pregnancy exclusion, medication effects, and clinical context still matter.

Can birth control hide POI?

Hormonal contraception can conceal or cause absent or irregular bleeding and can lower FSH. A clinician may direct a medication pause before confirmation. Do not stop contraception or HRT on your own for testing.

Does a low AMH mean I have POI?

No. AMH is an ovarian-reserve marker. It is not the primary POI diagnostic test and cannot establish the diagnosis without the required clinical and FSH context.

Does low AMH mean I cannot get pregnant naturally?

No. Low AMH can predict a lower response to ovarian stimulation, but it is a poor independent predictor of natural conception in women without diagnosed infertility. Age, reproductive history, sperm, tubes, ovulation, timing, and other factors matter.

Can periods return with POI?

Yes, in some nonsurgical cases. Ovarian activity can occur intermittently. A returning period does not prove POI has been reversed or predict the next cycle.

Can you get pregnant naturally with POI?

Yes, but the chance is low. The Menopause Society reports natural pregnancy in fewer than 10% of women with POI. That is a population estimate, not an individual monthly probability.

Do I still need contraception?

If you do not want a pregnancy and have nonsurgical POI, discuss contraception. Absent periods, irregular periods, and HRT do not provide reliable contraception.

Does HRT prevent pregnancy?

No. The current POI guideline states that HRT does not provide contraception.

Can POI be reversed?

No intervention has been reliably shown to restore ovarian activity or increase natural-conception rates. Spontaneous ovarian activity can recur, but that is unpredictable fluctuation rather than treatment-proven reversal.

Does having both ovaries removed count as POI?

Yes, when both ovaries are removed before 40. The international guideline treats that as established POI without further diagnostic testing. It is also accurately called surgical menopause.

Do I need hormone therapy if I feel fine?

Current guidance recommends HT until the usual age of menopause for most women with POI, even without obvious symptoms, to reduce long-term morbidity and mortality. Individual contraindications can change the plan.

How long should I use hormone therapy?

Generally until the usual age of menopause, followed by an individualized decision about continuing. Reaching 50 or 51 does not create an automatic stop date.

Does the WHI breast-cancer result apply directly to POI?

No. The WHI did not study young women replacing hormones after POI. Its original investigators wrote in 2024 that the hormone-trial findings should not be extrapolated to women with premature or early menopause because that group was not studied.

Can an online HRT provider diagnose POI?

A properly scoped telehealth clinician can evaluate and diagnose through telehealth, but many menopause platforms are not designed to complete the full genetic, autoimmune, fertility, bone, and specialist workup. Verify the provider’s actual scope before paying.

Can Midi Health treat me if I am under 35?

No. Midi’s current public eligibility language says it provides specialty care for women 35 and older.

Are compounded hormones FDA-approved?

No. Compounded drugs are not FDA-approved, and the FDA does not review them before marketing for safety, effectiveness, or quality in the same way as approved drugs. The current POI guideline does not recommend compounded estrogen or progesterone because efficacy and safety data are insufficient.

Sources

Current guideline and patient authorities

• ASRM/ESHRE: Evidence-based guideline—Premature Ovarian Insufficiency
• MedlinePlus: Primary Ovarian Insufficiency — updated May 21, 2026
• The Menopause Society: Premature Menopause
• NICE: Diagnosing Premature Ovarian Insufficiency
• ASRM: Testing and Interpreting Measures of Ovarian Reserve
• FDA: Compounding and the FDA—Questions and Answers

Studies and reviews

• Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open. 2024;2024(4):hoae065.
• Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017;318(14):1367–1376.
• Golezar S, Ramezani Tehrani F, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403–411.
• Li M, Zhu Y, Wei J, et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95–102.
• Alzubaidi NH, Chapin HL, Vanderhoof VH, et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstetrics & Gynecology. 2002;99(5 Pt 1):720–725.
• Csehely S, et al. Prevalence of Impaired Bone Health in Premature Ovarian Insufficiency and Early Menopause. 2025.
• Jones AR, Enticott J, Ebeling PR, et al. Long-term bone outcomes after premature ovarian insufficiency and early menopause. Human Reproduction. 2024;39(5):1013–1022.
• Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA. 2019;322(24):2411–2421.
• Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748–1760.
• Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature. American Journal of the Medical Sciences. 1942;204(5):625–648.

Coding and provider facts checked in August 2026

• CDC: ICD-10-CM files
• CMS FY2026 definitions manual: E28.310, E28.319, E28.39, E89.40, E89.41
• CDC March 2026 ICD-10 Coordination and Maintenance Committee packet
• Sesame fertility program
• Midi Health pricing and insurance
• Midi Health age eligibility
• Midi Health HRT options
• Midi Health compounded-option disclosure
• Midi cancellation and rescheduling policy

Still not sure which HRT path is right for you?

You came here with two confusing words. You are leaving with a diagnostic rule, a workup checklist, a fertility-and-contraception distinction, and a clearer idea of which door to knock on.

If the remaining question is which care route fits your age, insurance, state, medication preference, and clinical situation, use the tool built for that decision.

Take our free matching quiz—about 90 seconds, with no email needed to see your result.

→ Find My HRT Path

It will also tell you when online care is not the right starting point. For many women reading this page, that is exactly what it should say.

---

The HRT Index is an independent decision resource for online menopause and HRT care. This page is educational and is not medical advice. It has not been reviewed by a clinician—see our medical review policy and editorial standards. Diagnosis and treatment decisions belong to you and a licensed clinician. Last verified August 2026.